- Home
- WORX vs GRI Comparison
WORX vs GRI Comparison
Compare WORX & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WORX
- GRI
- Stock Information
- Founded
- WORX N/A
- GRI 2018
- Country
- WORX United States
- GRI United States
- Employees
- WORX N/A
- GRI N/A
- Industry
- WORX Services-Misc. Amusement & Recreation
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- WORX Consumer Discretionary
- GRI Health Care
- Exchange
- WORX Nasdaq
- GRI Nasdaq
- Market Cap
- WORX 3.6M
- GRI 4.3M
- IPO Year
- WORX N/A
- GRI N/A
- Fundamental
- Price
- WORX $0.29
- GRI $1.68
- Analyst Decision
- WORX
- GRI Strong Buy
- Analyst Count
- WORX 0
- GRI 2
- Target Price
- WORX N/A
- GRI $22.50
- AVG Volume (30 Days)
- WORX 3.1M
- GRI 186.9K
- Earning Date
- WORX 11-14-2025
- GRI 11-14-2025
- Dividend Yield
- WORX N/A
- GRI N/A
- EPS Growth
- WORX N/A
- GRI N/A
- EPS
- WORX N/A
- GRI N/A
- Revenue
- WORX $2,838,404.00
- GRI N/A
- Revenue This Year
- WORX N/A
- GRI N/A
- Revenue Next Year
- WORX N/A
- GRI N/A
- P/E Ratio
- WORX N/A
- GRI N/A
- Revenue Growth
- WORX N/A
- GRI N/A
- 52 Week Low
- WORX $0.26
- GRI $1.10
- 52 Week High
- WORX $3.31
- GRI $17.51
- Technical
- Relative Strength Index (RSI)
- WORX 48.29
- GRI 42.45
- Support Level
- WORX $0.27
- GRI $1.58
- Resistance Level
- WORX $0.34
- GRI $2.27
- Average True Range (ATR)
- WORX 0.03
- GRI 0.17
- MACD
- WORX -0.00
- GRI -0.05
- Stochastic Oscillator
- WORX 23.58
- GRI 14.49
About WORX SCWorx Corp.
SCWorx Corp is a provider of data content and services related to the repair, normalization, and interoperability of information for healthcare providers, as well as big data analytics for the healthcare industry. Its software enables a healthcare provider to simplify and organize its data, allows the data to be utilized across multiple internal software applications, and provides the basis for sophisticated data analytics. The company has developed and markets healthcare information technology solutions and associated services to improve healthcare processes and information flow within hospitals and other healthcare facilities.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.